Induction of Robust Immune Responses against Human Immunodeficiency Virus Is Supported by the Inherent Tropism of Adeno-Associated Virus Type 5 forDendritic Cells
Open accessThe DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Abstract
The ability of adeno-associated virus serotype 1 to 8 (AAV1 to AAV8) vectors expressing the human immunodeficiency virus type 1 (HIV-1) Env gp160 (AAV-HIV) to induce an immune response was evaluated in BALB/c mice. The AAV5 vector showed a higher tropism for both mouse and human dendritic cells (DCs) than did the AAV2 vector, whereas other AAV serotype vectors transduced DCs only poorly. AAV1, AAV5, AAV7, and AAV8 were more highly expressed in muscle cells than AAV2. An immunogenicity study of AAV serotypes indicates that AAV1, AAV5, AAV7, and AAV8 vectors expressing the Env gp160 gene induced higher HIV-specific humoral and cell-mediated immune responses than the AAV2 vector did, with the AAV5 vector producing the best responses. Furthermore, mice injected with DCs that had been transduced ex vivo with an AAV5 vector expressing the gp160 gene elicited higher HIV-specific cell-mediated immune responses than did DCs transduced with AAV1 and AAV2 vectors. We also found that AAV vectors produced by HEK293 cells and insect cells elicit similar levels of antigen-specific immune responses. These results demonstrate that the immunogenicity of AAV vectors depends on their tropism for both antigen-presenting cells (such as DCs) and non-antigen-presenting cells (such as muscular cells) and that AAV5 is a better vector than other AAV serotypes. These results may aid in the development of AAV-based vaccine and gene therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A functional copy of the RPE65 gene is delivered directly to the retinal cells using a single AAV gene delivery, restoring the patient’s vision [134].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [134]
In the citing paper
“Capsids with less transduction efficiency in APCs potentially have lower risk of induction of an immune response against the transgene [134–136].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [134]
Citations
Cites
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336 · cited 1×
“DCs are primarily responsible for stimulating resting naı̈ve T lymphocytes and initiating a CTL response (5).”
BackgroundPhenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544 · cited 1×
“A tetramer binding assay was used to identify major histocompatibility complex class I-restricted HIV-specific T cells (3).”
MethodNovel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 3×
“AAV2, AAV3, and AAV5 are found in humans, while AAV4, AAV7, and AAV8 are found in nonhuman primates (21, 45, 50).”
BackgroundKay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022
Xiao, X., Li, J., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8098-8108.1996 · Cited by 912
Site-specific integration by adeno-associated virus.
Kotin, R. M., Siniscalco, M., Samulski, R. J., Zhu, X. D., Hunter, L., Laughlin, C. A., McLaughlin, S., Muzyczka, N., Rocchi, M., & Berns, K. I. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.6.2211 · Cited by 868 · cited 1×
“The genome of wild-type AAV is known to integrate into the human genome at a specific site on chromosome 19q (36).”
BackgroundSite-specific integration by adeno-associated virus.
Linden, R. M., Ward, P., Giraud, C., Winocour, E., & Berns, K. I. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11288 · Cited by 805
Rabinowitz, J. E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., & Samulski, R. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.2.791-801.2002 · Cited by 762 · cited 2×
“Other AAV serotypes may have advantages as vaccine vectors because AAV serotypes differ in their tissue and/or cell tropism (23, 25, 30, 47).”
BackgroundAAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia
Xia, H., Mao, Q., Eliason, S. L., Harper, S. Q., Martins, I. H., Orr, H. T., Paulson, H. L., Yang, L., Kotin, R. M., & Davidson, B. L. (2004) · Nature Medicine · doi:10.1038/nm1076 · Cited by 652 · cited 1×
“3 and 4), which may be useful for gene therapy of diseases involving hematopoietic cells (4, 26, 43, 57, 59, 69).”
BackgroundSnyder, R. O., Miao, C. H., Patijn, G. A., Spratt, S. K., Danos, O., Nagy, D., Gown, A. M., Winther, B., Meuse, L., Cohen, L. K., et al. (1997) · Nature Genetics · doi:10.1038/ng0797-270 · Cited by 579 · cited 1×
“Using this vector system, exogenous genes have been efficiently transferred into a number of tissues, including brain (18), muscle (29), lung (19), gut (17), liver (55), and eye (37).”
BackgroundGain of Virulence Caused by Loss of a Gene in Murine Cytomegalovirus
Bubić, I., Wagner, M., Krmpotić, A., Saulig, T., Kim, S., Yokoyama, W. M., Jonjić, S., & Koszinowski, U. H. (2004) · Journal of Virology · doi:10.1128/jvi.78.14.7536-7544.2004 · Cited by 569
Gene therapy vectors based on adeno-associated virus type 1
Xiao, W., Chirmule, N., Berta, S. C., McCullough, B., Gao, G., & Wilson, J. M. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.3994-4003.1999 · Cited by 541 · cited 5×
“For example, AAV1 and AAV7 are more efficient than AAV2 for the transduction of skeletal muscle (21, 60), while AAV3 is superior for the transduction of megakaryocytes (27).”
BackgroundInfluentialDuan, D., Sharma, P., Yang, J., Yue, Y., Dudus, L., Zhang, Y., Fisher, K. J., & Engelhardt, J. F. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8568-8577.1998 · Cited by 522 · cited 1×
“However, in nondividing cells, AAV vector genomes mostly adopt the form of concatameric circular episomes that comprise active transcriptional units (16, 54).”
BackgroundFlotte, T. R., Afione, S. A., Conrad, C., McGrath, S. A., Solow, R., Oka, H., Zeitlin, P. L., Guggino, W. B., & Carter, B. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.22.10613 · Cited by 490
Herzog, R. W., Hagstrom, J. N., Kung, S.-H., Tai, S. J., Wilson, J. M., Fisher, K. J., & High, K. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.11.5804 · Cited by 474 · cited 1×
“Using this vector system, exogenous genes have been efficiently transferred into a number of tissues, including brain (18), muscle (29), lung (19), gut (17), liver (55), and eye (37).”
BackgroundJooss, K., Yang, Y., Fisher, K. J., & Wilson, J. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.5.4212-4223.1998 · Cited by 470 · cited 2×
“administration of the AAV vector but did not typically monitor cell-mediated immune responses against the encoded antigen (19, 32, 61).”
BackgroundSamulski, R. J., Berns, K. I., Tan, M., & Muzyczka, N. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.6.2077 · Cited by 466 · cited 1×
“Most of the current studies involving AAV are based on AAV2 since it was the first available infectious clone (51).”
BackgroundInsect Cells as a Factory to Produce Adeno-Associated Virus Type 2 Vectors
Urabe, M., Ding, C., & Kotin, R. M. (2002) · Human Gene Therapy · doi:10.1089/10430340260355347 · Cited by 457 · cited 2×
“To resolve the problem, AAV vectors have been produced utilizing baculovirus in insect cells (42, 56, 58) and herpes simplex virus (8, 14).”
BackgroundMethodSelf-citationRutledge, E. A., Halbert, C. L., & Russell, D. W. (1998) · Journal of Virology · doi:10.1128/jvi.72.1.309-319.1998 · Cited by 452 · cited 2×
“AAV2, AAV3, and AAV5 are found in humans, while AAV4, AAV7, and AAV8 are found in nonhuman primates (21, 45, 50).”
BackgroundLewin, A. S., Drenser, K. A., Hauswirth, W. W., Nishikawa, S., Yasumura, D., Flannery, J. G., & LaVail, M. M. (1998) · Nature Medicine · doi:10.1038/nm0898-967 · Cited by 407 · cited 1×
“Using this vector system, exogenous genes have been efficiently transferred into a number of tissues, including brain (18), muscle (29), lung (19), gut (17), liver (55), and eye (37).”
BackgroundIdentification of PDGFR as a receptor for AAV-5 transduction
Pasquale, G. D., Davidson, B. L., Stein, C. S., Martins, I., Scudiero, D., Monks, A., & Chiorini, J. A. (2003) · Nature Medicine · doi:10.1038/nm929 · Cited by 355 · cited 1×
“A primary coreceptor for AAV5 is sialic acid, while the platelet-derived growth factor receptor is involved in the binding and cell entry of AAV5 (15).”
BackgroundCloning and Characterization of Adeno-Associated Virus Type 5
Chiorini, J. A., Kim, F., Yang, L., & Kotin, R. M. (1999) · Journal of Virology · doi:10.1128/jvi.73.2.1309-1319.1999 · Cited by 332 · cited 1×
“Eight AAV serotypes (AAV1 to AAV8) have been described, with each serotype having unique binding and cell tropism characteristics (6, 11, 12, 21, 44, 50, 60).”
BackgroundZabner, J., Seiler, M., Walters, R., Kotin, R. M., Fulgeras, W., Davidson, B. L., & Chiorini, J. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.8.3852-3858.2000 · Cited by 315 · cited 2×
“AAV2, AAV4, and AAV5 infect cells of the central nervous system; however, differences with regard to the distribution and target cell types exist among these three serotypes (68).”
BackgroundHalbert, C. L., Allen, J. M., & Miller, A. D. (2001) · Journal of Virology · doi:10.1128/jvi.75.14.6615-6624.2001 · Cited by 314 · cited 1×
“AAV5 and AAV6 infect apical airway cells more efficiently (24, 68).”
BackgroundGenetic Fate of Recombinant Adeno-Associated Virus Vector Genomes in Muscle
Schnepp, B. C., Clark, K. R., Klemanski, D. L., Pacak, C. A., & Johnson, P. R. (2003) · Journal of Virology · doi:10.1128/jvi.77.6.3495-3504.2003 · Cited by 262 · cited 1×
“However, in nondividing cells, AAV vector genomes mostly adopt the form of concatameric circular episomes that comprise active transcriptional units (16, 54).”
BackgroundHalbert, C. L., Rutledge, E. A., Allen, J. M., Russell, D. W., & Miller, A. D. (2000) · Journal of Virology · doi:10.1128/jvi.74.3.1524-1532.2000 · Cited by 259 · cited 1×
“Other AAV serotypes may have advantages as vaccine vectors because AAV serotypes differ in their tissue and/or cell tropism (23, 25, 30, 47).”
BackgroundCloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles
Chiorini, J. A., Yang, L., Liu, Y., Safer, B., & Kotin, R. M. (1997) · Journal of Virology · doi:10.1128/jvi.71.9.6823-6833.1997 · Cited by 231 · cited 1×
“Eight AAV serotypes (AAV1 to AAV8) have been described, with each serotype having unique binding and cell tropism characteristics (6, 11, 12, 21, 44, 50, 60).”
BackgroundAbe, T., Hemmi, H., Miyamoto, H., Moriishi, K., Tamura, S., Takaku, H., Akira, S., & Matsuura, Y. (2005) · Journal of Virology · doi:10.1128/jvi.79.5.2847-2858.2005 · Cited by 226 · cited 1×
“This may be due to vector contamination by baculovirus components, since baculovirus itself can have an adjuvant effect on vaccine-induced immune responses (1, 22).”
BackgroundHybrid Vectors Based on Adeno-Associated Virus Serotypes 2 and 5 for Muscle-Directed Gene Transfer
Hildinger, M., Auricchio, A., Gao, G., Wang, L., Chirmule, N., & Wilson, J. M. (2001) · Journal of Virology · doi:10.1128/jvi.75.13.6199-6203.2001 · Cited by 207 · cited 3×
“Other AAV serotypes may have advantages as vaccine vectors because AAV serotypes differ in their tissue and/or cell tropism (23, 25, 30, 47).”
BackgroundUse of adeno-associated viral vector for delivery of small interfering RNA
Tomar, R. S., Matta, H., & Chaudhary, P. M. (2003) · Oncogene · doi:10.1038/sj.onc.1206733 · Cited by 196 · cited 1×
“3 and 4), which may be useful for gene therapy of diseases involving hematopoietic cells (4, 26, 43, 57, 59, 69).”
BackgroundVanbervliet, B., Homey, B., Durand, I., Massacrier, C., Aït-Yahia, S., Bouteiller, O. D., Vicari, A., & Caux, C. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200201)32:1<231::aid-immu231>3.0.co;2-8 · Cited by 171
Santosuosso, M., Zhang, X., McCormick, S., Wang, J., Hitt, M., & Xing, Z. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7986 · Cited by 166 · cited 1×
“The assay was performed as previously described (52).”
MethodBrockstedt, D. G., Podsakoff, G. M., Fong, L., Kurtzman, G., Mueller-Ruchholtz, W., & Engleman, E. G. (1999) · Clinical Immunology · doi:10.1006/clim.1999.4724 · Cited by 165 · cited 3×
“Consistent with previous studies, AAV-HIV vectors of different serotypes had distinct effects on the induction of HIVspecific humoral and cell-mediated immune responses (10, 17, 20, 28, 31, 38, 40, 53, 65, 66).”
BackgroundMethodResultNucleotide Sequencing and Generation of an Infectious Clone of Adeno-Associated Virus 3
Muramatsu, S.-I., Mizukami, H., Young, N. S., & Brown, K. E. (1996) · Virology · doi:10.1006/viro.1996.0367 · Cited by 159
Self-citationPeroral gene therapy of lactose intolerance using an adeno-associated virus vector
During, M. J., Xu, R., Young, D., Kaplitt, M. G., Sherwin, R. S., & Leone, P. (1998) · Nature Medicine · doi:10.1038/2625 · Cited by 158
Conway, J. E., Rhys, C. A., Zolotukhin, I., Zolotukhin, S., Muzyczka, N., Hayward, G. S., & Byrne, B. J. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300937 · Cited by 158 · cited 1×
“To resolve the problem, AAV vectors have been produced utilizing baculovirus in insect cells (42, 56, 58) and herpes simplex virus (8, 14).”
MethodBaculovirus Stimulates Antiviral Effects in Mammalian Cells
Gronowski, A. M., Hilbert, D. M., Sheehan, K. C. F., Garotta, G., & Schreiber, R. D. (1999) · Journal of Virology · doi:10.1128/jvi.73.12.9944-9951.1999 · Cited by 149 · cited 1×
“This may be due to vector contamination by baculovirus components, since baculovirus itself can have an adjuvant effect on vaccine-induced immune responses (1, 22).”
BackgroundXin, K.-Q., Hoshino, Y., Toda, Y., Igimi, S., Kojima, Y., Jounai, N., Ohba, K., Kushiro, A., Kiwaki, M., Hamajima, K., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0110 · Cited by 140
Self-citationFan, D.-S., Ogawa, M., Fujimoto, K.-I., Ikeguchi, K., Ogasawara, Y., Urabe, M., Nishizawa, M., Nakano, I., Yoshida, M., Nagatsu, I., et al. (1998) · Human Gene Therapy · doi:10.1089/10430349850019364 · Cited by 132
Self-citationHanda, A., Muramatsu, S.-I., Qiu, J., Mizukami, H., & Brown, K. E. (2000) · Journal of General Virology · doi:10.1099/0022-1317-81-8-2077 · Cited by 131 · cited 1×
“For example, AAV1 and AAV7 are more efficient than AAV2 for the transduction of skeletal muscle (21, 60), while AAV3 is superior for the transduction of megakaryocytes (27).”
BackgroundSelf-citationBantel-Schaal, U., Delius, H., Schmidt, R., & zur Hausen, H. (1999) · Journal of Virology · doi:10.1128/jvi.73.2.939-947.1999 · Cited by 128 · cited 1×
“Eight AAV serotypes (AAV1 to AAV8) have been described, with each serotype having unique binding and cell tropism characteristics (6, 11, 12, 21, 44, 50, 60).”
BackgroundManning, W. C., Paliard, X., Zhou, S., Pat Bland, M., Lee, A. Y., Hong, K., Walker, C. M., Escobedo, J. A., & Dwarki, V (1997) · Journal of Virology · doi:10.1128/jvi.71.10.7960-7962.1997 · Cited by 122
Sarukhan, A., Camugli, S., Gjata, B., von Boehmer, H., Danos, O., & Jooss, K. (2001) · Journal of Virology · doi:10.1128/jvi.75.1.269-277.2001 · Cited by 119 · cited 5×
“It has been known that adenovirus vectors may use both pathways; however, AAV2 relies on the latter pathway due to a low efficiency of transfection of DCs (53).”
BackgroundMethodResultInfluentialZhang, Y., Chirmule, N., Gao, G.-P., & Wilson, J. (2000) · Journal of Virology · doi:10.1128/jvi.74.17.8003-8010.2000 · Cited by 119 · cited 2×
“In this context, the levels of immune response induced by the AAV1HIV, AAV2-HIV, and AAV5-HIV vectors correlated with their tropism for DCs (70).”
BackgroundBuilding a Better Vector: The Manipulation of AAV Virions
Rabinowitz, J. E., & Samulski, R. J. (2000) · Virology · doi:10.1006/viro.2000.0707 · Cited by 117 · cited 1×
“Of note, while we used a prime/boost regimen involving repeated administration of the same AAV serotype vector, it may be even more effective to prime with one serotype and boost with another (since neutralizing Abs raised against the first vector are unlikely to cross-react with a different serotype) (48).”
MethodStructure of Adeno-Associated Virus Type 4
Padron, E., Bowman, V., Kaludov, N., Govindasamy, L., Levy, H., Nick, P., McKenna, R., Muzyczka, N., Chiorini, J. A., Baker, T. S., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.8.5047-5058.2005 · Cited by 108
Xin, K.-Q., Urabe, M., Yang, J., Nomiyama, K., Mizukami, H., Hamajima, K., Nomiyama, H., Saito, T., Imai, M., Monahan, J., et al. (2001) · Human Gene Therapy · doi:10.1089/104303401750214276 · Cited by 101 · cited 5×
“neoantigen was used to evaluate long-term expression (such as -galactosidase), the immune response elicited by our HIV Env gp160-encoding vector was quite strong (10, 17, 20, 28, 31, 38, 40, 53, 65, 66).”
BackgroundMethodResultInfluentialSelf-citationPonnazhagan, S., Mahendra, G., Curiel, D. T., & Shaw, D. R. (2001) · Journal of Virology · doi:10.1128/jvi.75.19.9493-9501.2001 · Cited by 91 · cited 3×
“An ex vivo experiment demonstrated that the AAV2 vector can transduce dendritic cells (DCs) and that these cells then present the AAV-encoded antigen to T cells (46, 65).”
BackgroundHara, H., Monsonego, A., Yuasa, K., Adachi, K., Xiao, X., Takeda, S., Takahashi, K., Weiner, H. L., & Tabira, T. (2004) · Journal of Alzheimer's Disease · doi:10.3233/jad-2004-6504 · Cited by 88 · cited 3×
“Consistent with previous studies, AAV-HIV vectors of different serotypes had distinct effects on the induction of HIVspecific humoral and cell-mediated immune responses (10, 17, 20, 28, 31, 38, 40, 53, 65, 66).”
BackgroundMethodResultJohnson, P. R., Schnepp, B. C., Connell, M. J., Rohne, D., Robinson, S., Krivulka, G. R., Lord, C. I., Zinn, R., Montefiori, D. C., Letvin, N. L., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.2.955-965.2005 · Cited by 87 · cited 3×
“Consistent with previous studies, AAV-HIV vectors of different serotypes had distinct effects on the induction of HIVspecific humoral and cell-mediated immune responses (10, 17, 20, 28, 31, 38, 40, 53, 65, 66).”
BackgroundMethodResultMeghrous, J., Aucoin, M. G., Jacob, D., Chahal, P. S., Arcand, N., & Kamen, A. A. (2008) · Biotechnology Progress · doi:10.1021/bp049802e · Cited by 81 · cited 1×
“To resolve the problem, AAV vectors have been produced utilizing baculovirus in insect cells (42, 56, 58) and herpes simplex virus (8, 14).”
MethodThe effects of DNA containing CpG motif on dendritic cells
Behboudi, S., Chao, D., Klenerman, P., & Austyn, J. (2000) · Immunology · doi:10.1046/j.1365-2567.2000.00979.x · Cited by 68
Hacker, U. T., Wingenfeld, L., Kofler, D. M., Schuhmann, N. K., Lutz, S., Herold, T., King, S. B. S., Gerner, F. M., Perabo, L., Rabinowitz, J., et al. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.782 · Cited by 63 · cited 1×
“Other AAV serotypes may have advantages as vaccine vectors because AAV serotypes differ in their tissue and/or cell tropism (23, 25, 30, 47).”
BackgroundGenetically Modified Dendritic Cells for Cancer Immunotherapy
Ribas, A. (2005) · Current Gene Therapy · doi:10.2174/156652305774964758 · Cited by 63 · cited 1×
“A number of studies show that recombinant AAV vectors can be used to transduce DCs (2, 13, 32, 35, 39, 46, 49, 53, 70).”
BackgroundLiu, Y., Santin, A. D., Mane, M., Chiriva-Internati, M., Parham, G. P., Ravaggi, A., & Hermonat, P. L. (2000) · Journal of Interferon & Cytokine Research · doi:10.1089/107999000312702 · Cited by 63 · cited 1×
“A number of studies show that recombinant AAV vectors can be used to transduce DCs (2, 13, 32, 35, 39, 46, 49, 53, 70).”
BackgroundMoore, M. D., McGarvey, M. J., Russell, R. A., Cullen, B. R., & McClure, M. O. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.739 · Cited by 62 · cited 1×
“3 and 4), which may be useful for gene therapy of diseases involving hematopoietic cells (4, 26, 43, 57, 59, 69).”
BackgroundXin, K.-Q., Ooki, T., Mizukami, H., Hamajima, K., Okudela, K., Hashimoto, K., Kojima, Y., Jounai, N., Kumamoto, Y., Sasaki, S., et al. (2002) · Human Gene Therapy · doi:10.1089/10430340260201662 · Cited by 61 · cited 7×
“neoantigen was used to evaluate long-term expression (such as -galactosidase), the immune response elicited by our HIV Env gp160-encoding vector was quite strong (10, 17, 20, 28, 31, 38, 40, 53, 65, 66).”
BackgroundMethodResultInfluentialSelf-citationXin, K.-Q., Jounai, N., Someya, K., Honma, K., Mizuguchi, H., Naganawa, S., Kitamura, K., Hayakawa, T., Saha, S., Takeshita, F., et al. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302590 · Cited by 60 · cited 1×
“say was performed as described elsewhere (63, 65).”
MethodSelf-citationYoshida, A., Tanaka, R. J., Murakami, T., Takahashi, Y., Koyanagi, Y., Nakamura, M., Ito, M., Yamamoto, N., & Tanaka, Y. (2003) · Journal of Virology · doi:10.1128/jvi.77.16.8719-8728.2003 · Cited by 57
Self-citationSollerbrant, K., Elmén, J., Wahlestedt, C., Acker, J., Leblois, H., Latta‐Mahieu, M., Yeh, P., & Perricaudet, M. (2001) · Journal of General Virology · doi:10.1099/0022-1317-82-9-2051 · Cited by 50
Transfection-free and scalable recombinant AAV vector production using HSV/AAV hybrids
Booth, M. J., Mistry, A., Li, X., Thrasher, A. J., & Coffin, R. S. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302226 · Cited by 46 · cited 1×
“To resolve the problem, AAV vectors have been produced utilizing baculovirus in insect cells (42, 56, 58) and herpes simplex virus (8, 14).”
MethodAttenuation of dengue virus infection by adeno-associated virus-mediated siRNA delivery
Zhang, W., Singam, R., Hellermann, G., Kong, X., San-Juan-Vergara, H. G., Lockey, R. F., Wu, S.-J., Porter, K. R., & Mohapatra, S. S. (2004) · Genetic Vaccines and Therapy · doi:10.1186/1479-0556-2-8 · Cited by 46
Han, W., Wind‐Rotolo, M., Kirkman, R. L., & Morrow, C. D. (2004) · Virology · doi:10.1016/j.virol.2004.09.027 · Cited by 41 · cited 1×
“3 and 4), which may be useful for gene therapy of diseases involving hematopoietic cells (4, 26, 43, 57, 59, 69).”
BackgroundAldrich, W. A., Ren, C., White, A. F., Zhou, S.-Z., Kumar, S., Jenkins, C. B., Shaw, D. R., Strong, T. V., Triozzi, P. L., & Ponnazhagan, S. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302601 · Cited by 40 · cited 1×
“A number of studies show that recombinant AAV vectors can be used to transduce DCs (2, 13, 32, 35, 39, 46, 49, 53, 70).”
BackgroundLiu, D., Chang, J., Tsao, Y., Huang, C., Kuo, S.-W., & Chen, S. (2004) · International Journal of Cancer · doi:10.1002/ijc.20530 · Cited by 31 · cited 3×
“Consistent with previous studies, AAV-HIV vectors of different serotypes had distinct effects on the induction of HIVspecific humoral and cell-mediated immune responses (10, 17, 20, 28, 31, 38, 40, 53, 65, 66).”
BackgroundMethodResultIn vivo Inhibition of Hippocampal Ca2+/Calmodulin-Dependent Protein Kinase II by RNA Interference
Babcock, A. M., Standing, D., Bullshields, K., Schwartz, E. A., Paden, C. M., & Poulsen, D. J. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.02.016 · Cited by 28
Jounai, N., Okuda, K., Kojima, Y., Toda, Y., Hamajima, K., Ohba, K., Klinman, D. M., & Xin, K.-Q. (2003) · The Journal of Gene Medicine · doi:10.1002/jgm.391 · Cited by 24 · cited 1×
“and enhanced immune responses against HIV Env gp160 in vivo (33).”
BackgroundSelf-citationGallez-Hawkins, G. M., Li, X., Franck, A. E., Thao, L., Lacey, S. F., Diamond, D. J., & Zaia, J. A. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.06.048 · Cited by 19 · cited 3×
“Consistent with previous studies, AAV-HIV vectors of different serotypes had distinct effects on the induction of HIVspecific humoral and cell-mediated immune responses (10, 17, 20, 28, 31, 38, 40, 53, 65, 66).”
BackgroundMethodResultKoppold, B., Sauer, G., Büning, H., Hallek, M. J., Kreienberg, R., Deißler, H., & Kurzeder, C. (2005) · International Journal of Oncology · doi:10.3892/ijo.26.1.95 · Cited by 9
A Sensitive Neutralization Test for the Adeno-Associated Satellite Viruses
Boucher, D. W., Parks, W. P., & Melnick, J. L. (1970) · The Journal of Immunology · doi:10.4049/jimmunol.104.3.555 · Cited by 8 · cited 1×
“The reservoir for AAV1 is unclear because these viruses have not been primarily isolated from tissues; however, reactive antibodies (Abs) against AAV1 have been found to exist in both humans and nonhuman primates (9).”
BackgroundRecombinant vaccinia virus (WR strain) may not be suitable for ex vivo stimulation
Xin, K.-Q., Kumamoto, Y., Jounai, N., Kojima, Y., Hamajima, K., & Okuda, K. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00437-1 · Cited by 2
Self-citation
Research works printed but not linked: 2
- 10.1002/1521-4141(200201)32:1<30::aid-immu30>3.0.co;2-e · DOI
- 10.1089/hum.1998.9.17-2527 · doi:10.1089/hum.1998.9.17-2527 · Paper page
Cited by
Developments in Viral Vector-Based Vaccines
Ura, T., Okuda, K., & Shimada, M. (2014) · Vaccines · doi:10.3390/vaccines2030624 · Cited by 436
“Many animal studies have examined vaccine vectors against HIV-1 [75–77], influenza [78], and papillomavirus [79].”
BackgroundSelf-citationReplicating and non-replicating viral vectors for vaccine development
Robert-Guroff, M. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.10.010 · Cited by 275
“AAV type 5 in particular has been shown to exhibit higher tropism for both mouse and human dendritic cells than AAV2, and to elicit potent cellular and humoral responses in mice [25].”
Immunity to adeno-associated virus vectors in animals and humans: a continued challenge
Zaiss, A. K., & Muruve, D. A. (2008) · Gene Therapy · doi:10.1038/gt.2008.54 · Cited by 180
Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery
Nidetz, N. F., McGee, M. C., Tse, L. V., Li, C., Cong, L., Li, Y., & Huang, W. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107453 · Cited by 174
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
Metadata
- Authors
- Xin, K.-Q., Mizukami, H., Urabe, M., Toda, Y., Shinoda, K., Yoshida, A., Oomura, K., Kojima, Y., Ichino, M., Klinman, D., Ozawa, K., & Okuda, K.
- Affiliations
- Yokohama City University (JP)
- Jichi Medical University (JP)
- Departments of Molecular Biodefense Research
- Center for Biologics Evaluation and Research (US)
- Corresponding author
- Okuda, Kenji
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2006-12-15
- Volume
- 80
- Issue
- 24
- Pages
- 11899-11910
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- PMC
- PMC1676308
- OpenAlex
- W2124799502
- Cited by
- 81
- References
- 72
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 3 · 2023: 5 · 2022: 3 · 2021: 3 · 2020: 1 · 2019: 6 · 2018: 2 · 2017: 1 · 2016: 1 · 2015: 5 · 2014: 5 · 2013: 5 · 2012: 3
- FWCI
- 4.37
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Virology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Biomedical Innovation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- dendritic cells, immunogenicity, HIV vaccine, gene therapy vectors, cell-mediated immunity, humoral immune response, muscle cells, antigen-presenting cells
- MeSH terms
- Dependovirus, Animals, beta-Galactosidase, Cell Line, Dendritic Cells, Enzyme-Linked Immunosorbent Assay, Genetic Vectors, HIV, Humans, Mice, Inbred BALB C, Transduction, Genetic, Blotting, Western, HIV Envelope Protein gp160, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.